TTrialPathMatch Me to Trials
← Back to trials
RecruitingRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Multiple MyelomaRefractory B-Cell Non-Hodgkin Lymphoma

A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This clinical trial evaluates whether an online cognitive training intervention (Intervention to enhance Cognitive Augmentation and Neuroplasticity \[I-CAN\]), delivered before and after treatment with chimeric antigen receptor T-cell therapy, works to improve cognitive and neurological outcomes in patients with multiple myeloma or B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Cancer treatment can have significant short and long-term side effects, including cognitive and neurological side effects such as impairments in attention, memory, language, and executive function. The I-CAN program is a form of cognitive training. Cognitive training is a therapeutic approach designed to improve and restore cognitive functioning, based on the brain's ability to reorganize and form new neural connections to accomplish tasks. I-CAN provides five core elements necessary for training the brain to create new neural connections including speed of processing, accuracy of processing, adaptivity, generalizability, and engagement. The I-CAN intervention, when delivered before and after therapy, may help reduce the cognitive side effects of treatment in patients with relapsed or refractory multiple myeloma or B-cell non-Hodgkin lymphoma.

Sponsor: Ohio State University Comprehensive Cancer Center

You may qualify if…

  • ✓ Patients \>= 18 years of age
  • ✓ Diagnosed with relapsed/refractory multiple myeloma (MM) or B-cell non-Hodgkin lymphoma (B-NHL)
  • ✓ Expected to receive an Food and Drug administration (FDA)-approved CAR-T cellular treatment
  • ✓ English literacy

You may not qualify if…

  • ✕ Patients expected to live \< 6 months
  • ✕ Patients with major medical disorder known to affect cognition, such as stroke, encephalitis, traumatic brain injury, brain surgery
  • ✕ Confirmed Alzheimer disease or other dementia
  • ✕ Previous central nervous system (CNS) radiation
  • ✕ Active intrathecal therapy at time of enrollment

Where it's recruiting

Ohio

Columbus

Source: ClinicalTrials.gov · NCT07609030 · last updated 2026-05-27

A Cognitive Training Intervention for Improving Cognitive and Neurolog · TrialPath